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Both types of diabetes are associated with higher incidence of some types of cancer. Treating cancer in
diabetic patients without aggravating diabetes-related complications is a challenge for clinicians.
Additionally, little is known about how diabetes affects the treatment of cancer. One of the most effective
chemotherapeutic drugs is cisplatin, which is nephrotoxic. Studies suggest that diabetes acts as a protec-
tive factor against the nephrotoxicity of cisplatin, but the mechanisms involved have not been elucidated
yet. This renal protection has been attributed to decreased accumulation of cisplatin in the kidneys,
which could be associated with deﬁcient active transport of proximal tubular cells or to pharmacokinetic
alterations caused by diabetes. However, it is uncertain if diabetes also compromises the antitumor activ-
ity of cisplatin. To address this issue, we developed a mouse model bearing cisplatin-induced nephrotox-
icity, Sarcoma 180 and streptozotocin-induced diabetes. Four groups of treatment were deﬁned: (i)
control, (ii) diabetic, (iii) cisplatin and (iv) diabetic treated with cisplatin. The following parameters were
evaluated: renal function, oxidative stress, apoptosis, renal histopathology, tumor remission, survival
rate, genotoxicity and platinum concentration in tumor and several organs. Results indicate that diabetes
protects against the renal damage induced by cisplatin, while also compromises its antitumor effective-
ness. This is the ﬁrst study to demonstrate this effect.
 2015 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Both types of diabetes mellitus (DM) have been associated with
increased risk of cancer. Type 2 diabetes is mainly associated with
increased risk of breast, colon, pancreatic and liver cancer, while
type 1 diabetes is associated with increase in cervical, stomach,
pancreatic, and endometrial cancer. The increased risk of cancer
in diabetes has been associated mainly with hyperglycemia and
hyperinsulinemia [50]. Hyperglycemia supplies the high demand
for glucose of tumor cells [78], while insulin is a hormonal stimu-
lator for cellular proliferation [48,80]. In addition, there is a clear
relationship between blood glucose reduction and remission of
malignant tumors [40]. A study in a model of breast cancer in mice
showed that higher values of glycaemia were associated with
higher mortality of those animals [58]. It is known that the kidneysof diabetic rats are protected against the nephrotoxicity induced by
structurally different compounds, including cisplatin; however, the
events underlying this protection are not clear [74,66,67,17]. Cis-
platin (cis-diamminedichloroplatinum II) is one of the most effec-
tive chemotherapeutic agents, but the exploitation of its full
therapeutic potential is limited predominantly due to its nephro-
toxicity [15,20,38,42]. The kidney is the main organ of excretion
of cisplatin and it is also the major site of cisplatin accumulation
[64]. The concentration of cisplatin in proximal tubular epithelial
cells is ﬁve times higher than in the serum [41]. The resistance
to nephrotoxicity is proportional to the duration and severity of
the diabetic state; low resistance is observed in rats after a week
of experimentally induced diabetes, and total resistance is found
after six weeks of uncontrolled diabetes experimentally induced
by streptozotocin. The resistance against the nephrotoxicity
induced by cisplatin has been found in both insulin-dependent
and insulin-independent diabetes [66,9,10]. The treatment of dia-
betic rats with insulin for 21 days abolishes the protection against
cisplatin-induced nephrotoxicity and increases the susceptibility
of animals to this toxicity [63]. The attenuation of cisplatin-
induced nephrotoxicity in diabetic rats has been associated with
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associated with decreased accumulation of platinum in the
kidneys, which has been attributed to deﬁciencies in the active
transport of the drug in tubular epithelial cells [9,62]. However,
it is uncertain whether the mechanisms involved in the diabetic
renal protection interfere with the antitumor activity of cisplatin
and this has been addressed in the present study. For this purpose,
we developed an experimental mouse model bearing cisplatin-
induced nephrotoxicity, Sarcoma-180-tumor and streptozotocin-
induced diabetes, which, to our knowledge, has not been
previously studied.
2. Materials and methods
2.1. Chemicals
High purity reagents were used (analytical grade minimum).
Reagents were obtained from Sigma–Aldrich, unless speciﬁed dif-
ferently. Type I ultra-pure water was obtained in the puriﬁcation
system by reverse osmosis (Rios DI-3), followed by puriﬁcation
in Milli-Q Gradient system (Millipore, Bedford, USA). Cisplatin
solution (1 mg/ml) was prepared in saline (0.9% NaCl) and strepto-
zotocin solution (15 mg/ml) was prepared in 50 mM sodium citrate
buffer, pH 4.5. Both were prepared immediately before use.
2.2. Tumor cells (Sarcoma 180, S-180)
Tumor cells were cultured in the ascites of mice for 8 days prior
to inoculation in other mice for development of solid tumor. To
preserve the tumor cell line, cells were grown (at 37 C in a humid-
iﬁed 5% CO2-containing atmosphere) in DMEM culture medium
(Dulbeccos Modiﬁed Eagle Medium) supplemented with 10% fetal
bovine serum (FBS) and 0.1% of antibiotic solution (PNS, 5 mg/ml of
penicillin, 5 mg/ml neomycin and 10 mg/ml streptomycin). For
preservation Sarcoma 180 cells were frozen in the same culture
medium previously described supplemented with 20% FBS and
10% DMSO (dimethylsulfoxide) [72,21].
2.3. Animal model
Swiss male adult mice (25–30 g) were housed four per cage and
were maintained in a 12-h light/dark cycle in a temperature (22–
24 C) and humidity (45–55%) controlled facility. Standard chow
and water were provided ad libitum. Animals were separated into
4 groups of treatment (n = 8 in each group) as follows:
(a) Control (C): Sarcoma180-tumor bearing mice without
treatment.
(b) CIS: Sarcoma180-tumor bearing mice treated with cisplatin.
(c) DB: Sarcoma180-tumor bearing diabetic mice without
treatment.
(d) DB + CIS: Sarcoma180-tumor-bearing, diabetic mice treated
with cisplatin.
Diabetes was induced by an injection (150 mg/kg, injection vol-
ume: 300 lL) of streptozotocin (15 mg/ml). After 10 days 80% of
animals presented levels of blood glucose above 250 mg/dl and
were considered diabetic. Sarcoma-180 cells from the ascites of
mice were injected (100 lL) subcutaneously in the ventral region
of other mice, just above the femoral muscle. A solid tumor devel-
oped after 8 days of inoculation [70]. Then, an intraperitoneal
injection (600 lL) of cisplatin (1 mg/ml) was administered in a sin-
gle dose (20 mg/kg). The survival rate assays were terminated
170 days after cisplatin treatment. In all other assays the animals
were euthanized after 72 h of cisplatin treatment. Blood samples
were collected for tests of renal function. The tumor and organs(kidneys, brain, testes, liver, skeletal muscle, heart and lung) were
removed immediately for the determination of platinum levels.
Research protocols were in strict accordance with the ‘‘Ethical
principles and guidelines for experiments on animals’’ of the Swiss
Academy of Medical Sciences and Swiss Academy of Sciences, and
were approved by the Ethics Committee on Animal Use (CEUA) of
Ribeirão Preto Campus – USP.
2.4. Assessment of the renal function
Urea and creatinine levels were measured in plasma by using
commercially available diagnostic kits (Labtest, MG, Brazil).
2.5. Preparation of kidney homogenate and protein determination
After euthanasia, the kidneys were immediately removed,
immersed in cold phosphate buffered saline (PBS) and kept in ice
bath. The cortex was carefully separated from the medullae,
weighed and homogenized in PBS (1:10) by using a Potter–Elveh-
jem type homogenizer (three 15-s cycles, 1-min intervals). The
homogenate was centrifuged at 350g for 10 min (4 C) and the
supernatant was removed for protein determination and oxidative
stress assays. Homogenate protein concentration was determined
by a spectrophotometric (Biuret, 540 nm) method [11].
2.6. Reduced glutathione (GSH)
The method previously described by Hissin and Hilf [31] was
used. Reduced glutathione was determined in kidney homogenate
by ﬂuorimetry (excitation 350 nm, emission 420 nm). A calibration
curve containing 7.5, 15, 30, 60, 150 and 300 mM of reduced gluta-
thione was used to calculate the concentrations of GSH in the
samples.
2.7. Lipid peroxidation
TBARS (thiobarbituric-acid-reactive substances) were deter-
mined in kidney homogenate by using the method previously
described by Buege and Aust [8]. The absorbance at 535 nm was
monitored and calculations were performed based on a calibration
curve containing 0.5, 1, 3, 10, 12.5, 15, 20 and 50 lM of 1,1,3,3-tet-
ramethoxypropane (TMOP).
2.8. NADPH oxidation
The method previously described by Lund et al. [46] was used.
NADPH oxidation was monitored by ﬂuorimetry (emission:
450 nm, excitation: 340 nm).
2.9. Histopathology
Kidneys were ﬁxed in paraformaldehyde (4%), dehydrated
through a series of graded ethanol baths (70%, 95% and 100%)
and embedded in parafﬁn. Tissue sections (4 lm) were placed on
slides, stained with H&E and the morphology was analyzed under
light microscopy (200). The percentage of damaged renal tubules
was calculated by counting ten different ﬁelds in the outer stripe of
the outer medulla and adjacent cortex per slide. The analysis of
longitudinal sections of renal tissue was performed by optical
microscopy (400). The degree of renal damage was analyzed
based on a scale from 0 to 4, deﬁned as follows: 0 = normal;
0.5 = small focal areas of cellular inﬁltration and tubular injury;
1 = lesion involving less than 10% of the cortex; 2 = injury involving
25% of the cortex; 3 = injury involving 25–50% of the cortex; and
4 = extensive damage involving more than 75% of cortex [69].
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The groups of animals (n = 8) were monitored daily for death
events until 170 days after cisplatin treatment, after which the
experiment was terminated. The analysis was performed as
previously described [24].
2.11. Tumor mass
After 72 h from the beginning of the treatment the animals
were euthanized, tumors were removed and weighed.
2.12. Genotoxicity of cisplatin
In order to determine the interference of diabetes in the geno-
toxicity of cisplatin and consequently in its antitumor activity,
we determined the frequency of micronuclei in peripheral blood
and the nuclear division index (NDI) in the bone marrow, as
described below.
2.12.1. Frequency of micronuclei in peripheral blood
This assay was performed according to the method previously
described [29]. After 24 and 72 h of the administration of cisplatin
blood was collected from the caudal vein and smeared on a micro-
scope slide. After 24 h, it was ﬁxed with methanol and dried for
10 min at room temperature. The slides were stained with acridine
orange (125 lg/ml, Sigma–Aldrich) 1 min prior to analysis with a
ﬂuorescence microscope Olympus BX 51 (488 nm, blue light,
yellow ﬁlter, 400). The presence of micronuclei in 2000 polychro-
matic erythrocytes (immature) was analyzed [12].
2.12.2. Nuclear division index (NDI) in bone marrow
The femur was removed and its ends were cut to give access to
the marrow canal, which then was ﬂushed with a syringe contain-
ing 2.0 ml of fetal bovine serum. The bone marrow cells were
gently mixed with the serum by repeatedly pulling and pushing
with the syringe [65,47]. The cells were centrifuged at 700g for
5 min and the supernatant was removed almost completely. The
pellet was mixed with the small residual volume of the superna-
tant and smeared on a microscope slide. The material was ﬁxed
in absolute methanol for 5 min and stained with Giemsa diluted
in phosphate buffer pH 6.8 (1:20) for 10 min. Polychromatic
(PCE) and normochromatic (NCE) erythrocytes were counted out
of 500 erythrocytes and the following equation was applied:
NDI = PCE/(PCE + NCE) [1].
2.13. Concentration of platinum in tumor and organs
A sample of tissue was weighed (15 a 85 mg), mixed with 1 ml
of a 50% solution (v/v) of tetramethylammonium (TMAH) hydrox-
ide and incubated for 48 h at room temperature. Next, 14 ml of dil-
uent solution (0.5% HNO3 (v/v) and 0.01% (v/v) Triton X-100) were
added. The 195 Pt isotope was monitored by mass spectrometry
with inductively coupled plasma (ICP-MS ELAN DRCII, PerkinEl-
mer) and quantiﬁcation was performed based on a calibration
curve (2; 5; 10:20 ppb platinum) prepared in the same diluent
solution. The platinum concentration was expressed in mg/g tissue
[4].
2.14. Immunohistochemistry for apoptosis evaluation
Kidney sections were dried overnight at 37 C, de-waxed in
xylene and re-hydrated in graded series of ethanol (100%, 95%,
70%), H2O and PBS. For antigen retrieval tissue sections were trea-
ted with proteinase K (20 lg/ml in 0.05 M Tris–HCl, 0.01 M CaCl2,
pH 8.0 buffer, Sigma) for 25 min at room temperature (RT).Endogenous peroxidase activity was blocked by immersion in 3%
hydrogen peroxide in PBS (30 min, RT). Unspeciﬁc bindings were
blocked with 2% horse serum in PBS (50 min, RT). Afterwards the
following procedures were performed.
2.14.1. Determination of caspase-3 and Bcl-2
Sections were incubated with primary antibodies (monoclonal
anti-caspase-3 or anti-Bcl-2, Santa Cruz Biotechnology, 4 lg/ml
in bovine serum albumin 1 mg/ml) for 12 h in a sealed humidity
chamber. Immunoreactivity was detected by using peroxidase
linked secondary antibody (poly – Max, Invitrogen). Visualization
of antibody localization was enhanced by diaminobenzidine
hydrochloride (DAB). Sections were rinsed three times with PBS
for 5 min, counterstained with hematoxylin (40 s), dehydrated in
ethanol, cleared in xylene, and mounted using Entelan (Merck)
mounting medium and glass coverslips. Sections were analyzed
under light microscopy (400 magniﬁcation). Quantitation was
performed by using ‘‘Image J’’ (1.44p Java 1.6, NIH) public access
program.
2.14.2. In situ direct DNA fragmentation (TUNEL) assay
The DNA fragmentation was assessed in kidney sections (4 lm)
by the TUNEL assay (ApopTag, Peroxidase In Situ Apoptosis Detec-
tion Kit, Chemicon), according to the manufacturer’s protocol.
Cells that were positively labeled were quantiﬁed in ten different
ﬁelds per slide under light microscopy (400 magniﬁcation). Posi-
tive labeled mammary gland cells provided in the kit were used as
positive controls.
2.15. Statistical analysis
Data were expressed as mean ± SEM. Statistical analyses were
conducted by the nonparametric Student’s t test (Mann–Whitney)
for comparison between each pair of groups (CIS  C; DB  C and
DB + CIS  CIS), except for histology in which Wilcoxon matched
pairs testwas applied. For the survival assay, the Kaplan–Meier sur-
vival method was employed and the Logrank test was used for the
comparison of the survival curves. All analyses were performed in
the GraphPad Prism Software, version 6 for Windows (GraphPad
Software, San Diego, CA, USA). Statistical signiﬁcance was deﬁned
as p < 0.05.
3. Results
3.1. Inoculation of Sarcoma 180 cells
Initially, the peritoneal cavity ﬂuid containing S-180 tumor cells
was diluted with PBS to obtain 5  107 cells/ml, and 100 ll of this
solution were injected in recipient animals, but cell viability was
low. In order to improve cell viability this procedure was modiﬁed
as follows: the peritoneal ﬂuid (average concentration: 2  108 -
cells/ml) was collected and directly injected into the recipient ani-
mals. This new procedure reduced from 15–20 days to 8 days the
time necessary for tumor to reach an approximate size of
0.96  0.75  0.81 mm.
Different regions of the body of mice were tested for cell inoc-
ulation by subcutaneous injection. The ventral region just above
the femoral muscle was chosen [57,70] because in this region the
tumor could be easily identiﬁed and removed, as shown in Fig. 1.
3.2. Treatment with streptozotocin to induce diabetes
Different doses of streptozotocin at different dose regimen were
tested. Intraperitoneal injection of 80 mg/kg once a day for ﬁve
consecutive days caused death before the end of experiment.
Fig. 1. Subcutaneous Sarcoma S-180 developed (a) above the femoral muscle and
(b) at the femoral muscle. In model (a) a well-deﬁned tumor is formed.
Experimental conditions are described in Section 2.
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dose regimen might cause nephrotoxicity [75], which would add
to the renal damage induced by cisplatin and jeopardize our
experimental model. Therefore, a single dose of 150 mg/kg [32]
was chosen. Animals whose blood glucose levels were at least
250 mg/dl at 10 days after streptozotocin injection were consid-
ered diabetic [36]. Approximately 15% of animals treated with this
dose of streptozotocin were not diabetic, which has also been
reported in another study [75].
3.3. Treatment with cisplatin: induction of nephrotoxicity
We evaluated different doses of cisplatin injected at the 8th day
after the inoculation of S-180 cells. Initially 8 mg/kg [57,33] was
tested; however, this concentration did not cause nephrotoxicity.
Then, animals were treated with different doses of cisplatin (15,
20, 25, 30, 35 and 40 mg/kg) at the 8th day after the inoculation
of S-180 cells. The dose 30 mg/kg caused nephrotoxicity, but it
caused excessive mortality in the group DB + CIS. The dose
15 mg/kg was not able to cause nephrotoxicity, i.e., there was no
signiﬁcant difference in urea and plasma creatinine between the
CIS and C groups. The lowest dose that caused nephrotoxicity
was 20 mg/kg, which has also been used by other authors [44].
3.4. Renal function
BUN (Fig. 2A) and plasma creatinine (Fig. 2B) were signiﬁcantly
higher in CIS (474.25 ± 62.95 and 2.23 ± 0.42, respectively) than inFig. 2. (A) Blood Urea Nitrogen (BUN). (B) Plasma creatinine. Values are expressed as mea
diabetic group and DB + CIS, diabetic group treated with cisplatin. ⁄Signiﬁcantly differen
conditions are described in Section 2.C (51.90 ± 2.22 and 0.26 ± 0.01 mg/dl, respectively) which indi-
cates the renal damage induced by cisplatin and validates the
experimental model of nephrotoxicity. There was a signiﬁcant
decrease in the concentrations of BUN and creatinine in DB + CIS
(101.60 ± 10.95 and 0.42 ± 0.03 mg/dl, respectively) as compared
to CIS (474.25 ± 62.95 and 2.23 ± 0.42, respectively), which
supports the renal protection conferred by diabetes that has been
reported in other studies [74,66,67]. There was no signiﬁcant dif-
ference in BUN and plasma creatinine between groups C
(51.90 ± 2.22 and 0.26 ± 0.01 mg/dl, respectively) and DB
(57.38 ± 4.75 and 0.26 ± 0.04 mg/dl, respectively).
3.5. Lipid peroxidation
Lipid peroxidation is a good marker of cellular dysfunction in
oxidative stress [30]. After lipid peroxidation various compounds
are formed by degradation of oxidized lipids. A classic and
common method for quantifying these compounds is based on a
colorimetric reaction with thiobarbituric acid [8]. In this study,
the oxidation of membrane lipids was determined by assessing
the thiobarbituric-acid-reactive substances (TBARS) in fresh
samples.
There was a signiﬁcant increase in TBARS in CIS (0.79 ±
0.08 nmol/mg protein) as compared to C (0.12 ± 0.01 nmol/mg
protein). TBARS decreased signiﬁcantly in DB + CIS (0.06 ±
0.01 nmol/mg protein) as compared to CIS (0.79 ± 0.08 nmol/mg
protein). There was no signiﬁcant difference in TBARS between
DB (0.17 ± 0.05 nmol/mg protein) and C (0.12 ± 0.01 nmol/mg
protein). Results are presented in Fig. 3.
3.6. GSH
CIS (1.34 ± 0.18 nmol/mg protein) and DB (1.32 ± 0.17 nmol/mg
protein) presented a signiﬁcantly decreased concentration of GSH
in relation to C (2.19 ± 0.21 nmol/mg protein). No signiﬁcant differ-
ence was observed between DB + CIS (1.45 ± 0.10 nmol/mg pro-
tein) and CIS (1.34 ± 0.18 nmol/mg protein). Results are
presented in Fig. 4.
3.7. NADPH
No signiﬁcant differences were observed between the pairs of
compared groups: CIS (91.94 ± 0.31) or DB (94.92 ± 0.25) versus C
(100.0 ± 0.34); and DB + CIS (88.08 ± 0.17) versus CIS
(91.94 ± 0.31). Results are presented in Fig. 5.
3.8. Histopathology of the renal tissue
The histopathological changes of renal tissue caused by cis-
platin were evaluated in hematoxylin-and-eosin stained (H&E)n ± SEM (n = 8) of assays performed in triplicates. C, control; CIS, cisplatin group; DB,
t from control (p < 0.05); #signiﬁcantly different from CIS (p < 0.05). Experimental
Fig. 3. Lipid peroxidation in mice kidney homogenates. Values are expressed as
mean ± SEM (n = 8) of assays performed in triplicates. C, control; CIS, cisplatin
group; DB, diabetic group and DB + CIS, diabetic group treated with cisplatin.
⁄Signiﬁcantly different from control (p < 0.05); #signiﬁcantly different from CIS
(p < 0.05). Experimental conditions are described in Section 2.
Fig. 5. NADPH in mice kidney homogenates. Values are expressed as mean ± SEM
(n = 8) of assays performed in triplicates. C, control; CIS, cisplatin group; DB,
diabetic group and DB + CIS, diabetic group treated with cisplatin. No signiﬁcant
differences were observed between CIS versus C, DB versus C or DB + CIS versus CIS.
The intensity of ﬂuorescence was normalized to 100% in control. Experimental
conditions are described in Section 2.
Table 1
Histopathology: lesion scores in the renal tissue.
Groups Lesion scores
C 1.64 ± 0.32
CIS 4.00 ± 0.02*
DB + CIS 2.57 ± 0.20#
DB 2.12 ± 0.22
Values are expressed as mean ± SEM (n = 8). The longitudinal sections of kidney
tissue were analyzed according to the degree of injury of the cortex by using a scale
from 0 to 4. Scores meaning: 0 = normal; 0.5 = some focal areas of cellular inﬁl-
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show signiﬁcantly different scores of tubular damage, conﬁrming
that the dose regimen of streptozotocin did not induce renal injury.
The CIS group (4.00 ± 0.05) showed a lesion score signiﬁcantly
higher than C (1.64 ± 0.32). These data are consistent with the
renal function results, and conﬁrm cisplatin-induced nephrotoxi-
city in our experimental model. DB + CIS (2.57 ± 0.20) showed a
signiﬁcantly reduced lesion score as compared to CIS
(4.00 ± 0.05). The lesion scores are presented in Table 1 and the
photomicrographs are presented in Fig. 6.tration and tubular injury; 1 = lesion involving less than 10% of the cortex;
2 = injury involving 25% of the cortex; 3 = injury involving 50–75% of the cortex;
and 4 = extensive damage involving more than 75% of the cortex.
* Signiﬁcantly different from C (p < 0.05).
# Signiﬁcantly different from CIS (p < 0.05). No signiﬁcant difference was
observed between C and DB. Experimental conditions are described in Section 2. C,
control; CIS, cisplatin group; DB, diabetic group; DB + CIS, diabetic group treated
with cisplatin.3.9. Survival rate
The survival curves of the groups were signiﬁcantly different
(Logrank test, P value < 0.0001). The median survival was signiﬁ-
cantly lower in DB + CIS (17.5) than in CIS (48.5) probably due to
the impaired antitumor action of cisplatin in the DB + CIS group.
There was no signiﬁcant difference between the median survival
in the control group (65) and in the CIS group (62.5), however,
while all the animals in the control group died within 100 days,Fig. 4. GSH in mice kidney homogenates. Values are expressed as mean ± SEM
(n = 8) of assays performed in triplicates. C, control; CIS, cisplatin group; DB,
diabetic group and DB + CIS, diabetic group treated with cisplatin. ⁄Signiﬁcantly
different from control (p < 0.05). Experimental conditions are described in Section 2.25% of animals in CIS survived at least 170 days, when the assay
was terminated. Animals in the DB group died within 55 days
and in the DB + CIS group died within 27 days, which indicates that
cisplatin treatment was not beneﬁcial in this group. The survival
curves are depicted in Fig. 7.3.10. Tumor mass
Tumor mass was signiﬁcantly reduced in CIS (0.19 ± 0.02 g) as
compared to C (0.61 ± 0.07 g), which demonstrates the antitumor
efﬁcacy of cisplatin. There was no signiﬁcant difference in tumor
mass between groups C (0.61 ± 0.07 g) and DB (0.69 ± 0.14 g), both
without cisplatin treatment. The CIS + DB group showed signiﬁ-
cantly higher tumor mass (0.32 ± 0.02 g) as compared to CIS
(0.19 ± 0.02). These data suggest that the antitumor activity of cis-
platin was affected by diabetes (Fig. 8).3.11. Platinum biodistribution
The biodistribution of cisplatin in the tumors and in several
organs was evaluated based on the concentration of platinum. In
Fig. 6. Histopathology. Representative photomicrographs of H&E stained longitudinal sections of kidney tissue (400). Groups: (A) control; (B) CIS; (C) DB and (D) DB + CIS.
Experimental conditions are described in Section 2. CIS, cisplatin; DB, diabetic; DB + CIS, diabetic treated with cisplatin.
Fig. 7. Survival rate. The total number of animals in each group (n = 8) was
normalized to 100%. Experiment was terminated 170 days after cisplatin treatment
and only in the CIS group there were animals alive. CIS, cisplatin; DB, diabetic;
DB + CIS, diabetic treated with cisplatin. Experimental conditions are described in
Section 2.
Fig. 8. Tumor mass. Values are expressed as mean ± SEM (n = 8). C, control; CIS,
cisplatin group; DB, diabetic group and DB + CIS, diabetic group treated with
cisplatin. ⁄Signiﬁcantly different from control (p < 0.05); #signiﬁcantly different
from CIS (p < 0.05). Experimental conditions are described in Section 2.
Table 2
Concentration of platinum in different tissues (lg/g).
TISSUES C CIS CIS + DB DB
Tumor 6LOD 17.09 ± 1.20* 7.98 ± 1.24# 6LOD
Kidneys 6LOD 32.72 ± 4.64* 12.25 ± 1.28# 6LOD
Liver 6LOD 325.81 ± 15.70* 21.98 ± 2.73# 6LOD
Brain 6LOD 0.668 ± 0.07* 0.389 ± 0.02# 6LOD
Testicles 6LOD 8.76 ± 0.83* 5.71 ± 0.64# 6LOD
Heart 6LOD 5.44 ± 0.59* 2.7 ± 0.35# 6LOD
Muscle 6LOD 4.86 ± 0.33* 2.65 ± 0.37# 6LOD
Lungs 6LOD 13.16 ± 1.57* 6.89 ± 0.97# 6LOD
C, control; CIS, cisplatin group; DB, diabetic group and DB + CIS, diabetic group
treated with cisplatin; LOD, low limit of quantitation = 0.006 lg/g.
* Signiﬁcantly different from C (p < 0.05).
# Signiﬁcantly different from CIS (p < 0.05). No signiﬁcant difference was
observed between C and DB. Data are expressed as mean ± SEM (n = 8). Experi-
mental conditions are described in Section 2.
Table 3
Nuclear division index (NDI) in bone marrow.
Groups NDI
C 0.65 ± 0.03
CIS 0.14 ± 0.03*
DB + CIS 0.51 ± 0.04#
DB 0.68 ± 0.03
C, control; CIS, cisplatin group; DB, diabetic group and DB + CIS, diabetic group
treated with cisplatin.
* Signiﬁcantly different from C (p < 0.05).
# Signiﬁcantly different from CIS (p < 0.05). No signiﬁcant difference was
observed between C and DB. Data are expressed as mean ± SEM (n = 8). Experi-
mental conditions are described in Section 2.
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concentrations of platinum in the tumor and in all the organs were
signiﬁcantly higher in CIS than in C (p < 0.05) and signiﬁcantly
lower in CIS + DB than in CIS (Table 2).
Fig. 9. Micronucleus assay. (A–D) Representative photomicrographs of peripheral blood and bone marrow cells of the CIS group. (A and C) peripheral blood cells (24 h-
treatment) stained with acridine-orange; (B) bone marrow cells (72 h-treatment) stained with Giemsa; (D) peripheral blood cells (72 h- treatment) stained with acridine-
orange. Magniﬁcation: (A) 1000; (B–D) 400. (E) Graphical representation of the frequency of polychromatic erythrocytes with micronuclei in peripheral blood after 24 h of
cisplatin treatment. Values are expressed as mean ± SEM (n = 8) of MNPCE/1000 erythrocytes. Experimental conditions are described in Section 2. ⁄Signiﬁcantly different from
control (p < 0.05); #signiﬁcantly different from CIS (p < 0.05) MNPCE, polychromatic erythrocytes with micronuclei; PCE, polychromatic erythrocyte; NCE, normochromatic
erythrocyte; C, control; CIS, cisplatin group; DB, diabetic group and DB + CIS, diabetic group treated with cisplatin.
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After 24 h of cisplatin administration, the CIS group presented
increased number of micronuclei (MN) as compared to C. After
72 h of cisplatin administration, it was not possible to quantify
the number of polychromatic erythrocytes (PCE) or immature
erythrocytes, probably due to the inhibition of cell proliferation
induced by cisplatin, which was conﬁrmed by the nuclear divi-
sion index (NDI) in bone marrow. A decrease in the ratio PCEs/
NCEs (NDI) in bone marrow indicates cellular toxicity with myel-
osuppression [23,27]. In our study, CIS presented a signiﬁcant
reduction in NDI as compared to C (p < 0.05), which indicates
the occurrence of myelosuppression in CIS. The DB + CIS group
showed signiﬁcant reduction in the number of micronuclei and
higher NDI when compared to CIS (p < 0.05), suggesting that dia-
betes interferes with the genotoxic and cytotoxic activities ofcisplatin diminishing its antitumor activity. No signiﬁcant differ-
ences were observed between C and DB for micronuclei or NDI.
The values of NDI are presented in Table 3, the photomicro-
graphs of erythrocytes are presented in Fig. 9A–D and the quan-
titative analysis is presented in Fig. 9E.3.13. Expression of caspase-3
The expression of caspase-3 increased signiﬁcantly in CIS
(19.60 ± 1.66) as compared to C (2.20 ± 0.15); whereas in DB + CIS
(2.86 ± 0.32) it was signiﬁcantly reduced in relation to CIS
(19.60 ± 1.66). No signiﬁcant difference was observed between C
(2.20 ± 0.15) and DB (1.74 ± 0.17). Photomicrographs are presented
in Fig. 10A–D and the quantitative analysis is presented in Fig. 10E.
Fig. 10. Expression of caspase-3. (A–D) Representative photomicrographs of caspase-3 immunohistochemistry in renal tissue (400 magniﬁcation). (A) Control; (B) CIS; (C)
DB and (D) CIS + DB. (E) Graphical representation of quantitative analysis. Values are expressed as mean ± SEM. C, control; CIS, cisplatin group; DB, diabetic group and
DB + CIS, diabetic group treated with cisplatin. ⁄Signiﬁcantly different from control (p < 0.05); #signiﬁcantly different from CIS (p < 0.05). Experimental conditions are
described in Section 2.
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The expression of the antiapoptotic protein Bcl-2 increased sig-
niﬁcantly in CIS (29.37 ± 2.38) as compared to C (1.14 ± 0.15);
while it decreased signiﬁcantly in DB + CIS (3.00 ± 0.58) as com-
pared to CIS (29.37 ± 2.38). No signiﬁcant difference was observed
between C (1.14 ± 0.15) and DB (2.02 ± 0.42). Photomicrographs
are presented in Fig. 11A–D and the quantitative analysis is pre-
sented in Fig. 11E.
3.15. TUNEL assay
The CIS group (57.75 ± 7.88) showed a signiﬁcant increase in
the number of TUNEL positive cells in the renal cortex and medulla
compared to group C (1.37 ± 0.60). The CIS + DB group (4.63 ± 1.43)
showed a signiﬁcant reduction in TUNEL positive cells when com-
pared to CIS (57.75 ± 7.88) indicating that diabetes decreases cis-
platin-induced apoptosis in renal tissue. There was no signiﬁcant
difference between groups C (1.37 ± 0.60) and DB (1.80 ± 0.86).Photomicrographs are presented in Fig. 12A–D and the quantita-
tive analysis is presented in Fig. 12E.
4. Discussion
Treatment of cancer in diabetic patients presents a unique chal-
lenge to clinicians. Additionally, these patients might not be prop-
erly addressed in clinical studies, and the information on how
diabetes affects cancer treatment is limited [22,54,52]. It is known
that diabetes attenuates the nephrotoxicity induced by cisplatin in
animal models and that this attenuation is dependent on the sever-
ity of the diabetic state [66]. However, it is unclear if diabetes
interferes in the antitumor activity of cisplatin. Therefore, we
established a mouse model bearing: (i) diabetes, (ii) Sarcoma-180
and (iii) cisplatin-induced nephrotoxicity, in order to study the
mechanisms by which diabetes attenuates the nephrotoxicity of
cisplatin and if these mechanisms interfere in the antitumor activ-
ity of the drug. To our knowledge this is the ﬁrst study to use an
animal model with these three conditions to address these issues.
Fig. 11. Expression of Bcl-2. (A–D) Representative photomicrographs of Bcl-2 immunohistochemistry in renal tissue. (A) Control; (B) CIS; (C) DB and (D) CIS + DB. 400
magniﬁcation. (E) Graphical representation of quantitative analysis. Values are expressed as mean ± SEM. ⁄Signiﬁcantly different from control (p < 0.05); #signiﬁcantly
different from CIS (p < 0.05). Experimental conditions are described in Section 2. C, control; CIS, cisplatin group; DB, diabetic group and DB + CIS, diabetic group treated with
cisplatin.
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injury has not been fully elucidated [81,73], but it is known that
the damage caused in kidney is proportional to the dose [53].
The dose used in this study was high enough to cause extensive
damage involving more than 75% of the total area of the cortex,
as revealed by histopathology. Diabetes was induced with a single
administration of 150 mg of streptozotocin/kg in mice, a dose that
did not cause renal damage, as conﬁrmed by BUN and plasma cre-
atinine of the DB group (diabetic mice not treated with cisplatin).
Studies show that high doses of streptozotocin can cause nonspe-
ciﬁc toxicity, affecting different organs, including the kidneys,
while low doses affect only the pancreatic beta cells, inducing type
1 diabetes by reducing insulin production and leading to hypergly-
cemia [75,79].
Our previous studies with mitochondria isolated from renal cor-
tex of rats treated with cisplatin [59,60], showed that cisplatin-
induced nephrotoxicity was associated with mitochondrial lipid
peroxidation, GSH and NADPH depletion, markers of oxidativestress. In the present study, these markers were evaluated in
homogenates of the renal cortex and only lipid peroxidation and
GSH depletion were induced by cisplatin, with no signiﬁcant
change in the concentration of NADPH. It is known that there is
an important correlation between homeostasis of GSH and NADPH
as both participate in the defense against reactive oxygen species
(ROS) generated mainly in mitochondria, the main cellular site
generator of ROS [7]. Therefore, this difference between the ﬁnd-
ings in mitochondria and in the kidney homogenate could be
attributed to the greater oxidative stress generated in mitochon-
dria, capable of oxidizing the mitochondrial GSH and consequently
the mitochondrial NADPH, which is consumed by glutathione
reductase to restore the stocks of GSH from its oxidized form
(GSSG). Additionally, it is known that cisplatin generates electro-
philic intermediates capable of reacting with SH groups (nucleo-
philes), which would explain the depletion of GSH without
formation of GSSG and consequently, without NADPH depletion.
A predominance of the ﬁrst mechanism (oxidation of NADPH and
Fig. 12. TUNEL assay. (A–D) Representative photomicrographs showing TUNEL-positive cells in renal tissue (400 magniﬁcation). (A) Control; (B) DB; (C) CIS (D) and (D)
DB + CIS. (E) Graphical representation of quantitative analysis. Values are expressed as mean ± SEM. ⁄Signiﬁcantly different from control (p < 0.05); #signiﬁcantly different
from CIS (p < 0.05). Experimental conditions are described in Section 2. C, control; CIS, cisplatin group; DB, diabetic group and DB + CIS, diabetic group treated with cisplatin.
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platin adducts) in the whole cell could explain these results. The
DB group presented depletion of GSH but not lipid peroxidation,
which suggests that the cellular redox state was already altered
but the oxidation of macromolecules had not started yet. Con-
trarily, a study reported a signiﬁcantly increased lipid peroxidation
and a markedly diminished GSH in the liver of streptozotocin dia-
betic rats [37]. Another study reported increased formation of lipid
peroxides but unchanged GSH content in the kidneys of streptozo-
tocin diabetic rats [6]. These apparent conﬂicting ﬁndings might be
due to the dynamics of the process, which depends on the severity
of the insult. The insult triggers a sequence of biochemical events:
ﬁrst, reactive oxygen species (ROS) and free radicals are generated
leading to decrease of GSH which will alter the cellular redox state
and progress until a pro-oxidant state is established, favoring the
oxidative damage to macromolecules, such as lipids [2,51]. There-
fore, depending on the conditions of the experiment, the ﬁndings
might not be parallel, i.e., GSH is already decreased but not sufﬁ-ciently to allow the oxidative damage to lipids and other
macromolecules.
Although kidneys are the main site of accumulation of cisplatin,
we found high concentration of platinum in the liver. This effect
could be attributed to the high dose of cisplatin used in our studies
because it is known that high doses of cisplatin are associated with
other toxicities, mainly hepatotoxicity [15,18]. Our ﬁndings are in
line with other studies that suggest that attenuation of cisplatin-
induced nephrotoxicity in diabetic rats is associated with
decreased renal accumulation of platinum, which in turn has been
attributed in part to deﬁciencies in the active transport of the drug
[9,62]. The lower renal accumulation of cisplatin and other nephro-
toxic agents appears to be associated with the diuretic glycosuria
characteristic of diabetes [67] and/or changes in the bioavailability
of the drug [61]. A study in rats with diabetes experimentally
induced by streptozotocin suggested that the renal organic cation
transporter (OCT1 and OCT2) might be altered due to glycosylation
of one or more of its components [26]. Our study is the ﬁrst to
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platin not only in the kidney but also in other organs and especially
in the tumor. Additionally, tumor remission was lower in the
DB + CIS group. Taken together, these ﬁndings suggest that the
mechanism of renal protection exerted by diabetes likely involves
changes in the biodistribution of cisplatin, compromising its anti-
cancer activity. The impairment of the antitumor activity of cis-
platin induced by diabetes had not been previously demonstrated.
The micronucleus assay detects the genotoxic activity of chem-
ical and physical agents. The genotoxic activity of cisplatin is
attributed to intrastrand and interstrand cross-links with purine
bases of DNA, with consequent formation of DNA-cisplatin adducts
and distortion of the DNA double helix [56,39,77]. This distortion
interferes with the normal mechanisms of DNA transcription and
replication, therefore inhibiting cell proliferation and causing cell
death ([3,68]. One potentially important way by which cisplatin-
DNA adducts may kill cells is by induction of programmed cell
death or apoptosis [19,25]. Although the genotoxicity of cisplatin
also damages healthy cells, its effects on tumor cells are more pro-
nounced, since these cells are in the process of uncontrolled cell
division. Thus, although other mechanisms are involved in the
cytotoxicity of cisplatin, particularly those related to the
production of reactive oxygen species (ROS), it is believed that
the genotoxic action is the main mechanism involved in the antitu-
mor action of cisplatin and that ROS are mainly responsible for the
toxicity in healthy tissues, particularly in kidneys [34,60,3]. In our
study, the genotoxicity of cisplatin was demonstrated by the sig-
niﬁcantly increased frequency of micronuclei (MN) in the CIS
group as compared to the control group, 24 h after the administra-
tion of cisplatin. After 72 h of cisplatin administration, it was not
possible to quantify the number of polychromatic (PCE) or imma-
ture erythrocytes, probably due to the severe inhibition of cell pro-
liferation induced by cisplatin, as demonstrated by the nuclear
division index (NDI) in bone marrow. NDI corresponds to polychro-
matic/normochromatic erythrocytes ratio (PCEs/NCEs) and its
decrease is associated with toxicity in bone marrow cells and
myelosuppression [23]. In our study, CIS showed signiﬁcant
reduction in NDI as compared to control, which is indicative of
myelosuppression [27]. The DB + CIS group showed a signiﬁcant
reduction in the frequency of micronuclei and in NDI (myelosup-
pression) when compared to CIS, which indicates that diabetes
interferes with genotoxicity/cytotoxicity of cisplatin and contrib-
utes to reduce the efﬁciency of its antitumor activity.
Apoptosis is an important mechanism of cell death associated
with the renal damage induced by cisplatin [16,28,77]. In our
study, the characterization of apoptosis was performed by TUNEL
assay and evaluation of the molecular biomarkers, caspase-3 and
Bcl-2.
Caspase-3 plays a crucial role in apoptosis being responsible for
the activation of DNA endonucleases, cleavage and fragmentation
of DNA and formation of apoptotic DNA [45]. Our research group
[59] and other authors [35] have demonstrated increased
activity/expression of caspase-3 in kidneys of rats treated with cis-
platin. Our present ﬁndings conﬁrm the induction of apoptosis by
cisplatin in renal cells and indicate that diabetes protected against
this effect in this experimental model, which is in line with the
nephroprotective effect of diabetes indicated by other studies
[66,62].
The anti-apoptotic protein Bcl-2 plays an important role in
apoptosis regulation, both in physiological and pathological condi-
tions [5,71]. Bcl-2 prevents the loss of mitochondrial membrane
potential, release of cytochrome c into the cytosol and conse-
quently, the activation of caspases by the mitochondrial pathway
[13,71,14,76]. It is known that overexpression of Bcl-2 inhibits
the activation of caspase-3 [55], but in our experimental model
we observed increased expression of both proteins in the CIS groupas compared to control. The apparently contradictory increase of
both Bcl-2 (anti-apoptotic) and caspase-3 (effector of apoptosis)
could be attributed to a temporary cell response to the activation
of caspase-3, as an attempt to counteract the apoptotic process
triggered by cisplatin. A study to evaluate the nephroprotective
potential of sildenaﬁl in rats treated with cisplatin also reported
increased expression of caspase-3 and Bcl-2, but after 96 h of cis-
platin treatment [43]. In our study, the increase in Bcl-2 was higher
than in the previous study and was observed 72 h after cisplatin
treatment. The DB + CIS group had a signiﬁcant reduction in the
expression of Bcl-2 as compared to the CIS group. Since caspase-
3 was signiﬁcantly lower in DB + CIS than in control, this result is
in line with our hypothesis that the increase of Bcl-2 would be a
cellular response to counteract the apoptosis already initiated.
The detection of apoptosis by TUNEL assay conﬁrms caspase-3
results and the morphological alterations found, and it is also in
line with previous studies in different experimental models
[82,43].5. Conclusions
The experimental model is suitable for the study of the antitu-
mor activity of cisplatin in diabetic animals and might be adjusted
to evaluate the effects of diabetes on other drugs. Diabetes
decreases lipid peroxidation, apoptosis and the histopathological
changes induced by cisplatin in kidneys, but has no effect on
GSH depletion. It also decreases platinum accumulation in multiple
organs and tumor, decreases tumor remission, survival rate (in cis-
platin-treated animals) and the genotoxicity of cisplatin. This is the
ﬁrst study to demonstrate that diabetes-induced protection from
cisplatin nephrotoxicity is associated with impairment of the anti-
tumor activity of the drug.Conﬂicts of Interest
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